Manuel J Cuesta Selected Research

Polytetrafluoroethylene (Teflon)

11/2022	Cortical thinning over two years after first-episode psychosis depends on age of onset.
6/2022	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode.
6/2022	Neuromotor dysfunction as a major outcome domain of psychotic disorders: A 21-year follow-up study.
1/2022	Impact of traumatic life events on clinical variables of individuals with first-episode psychosis and healthy controls.
1/2022	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?
1/2022	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort.
1/2022	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses.
1/2022	The network structure of cognitive deficits in first episode psychosis patients.
11/2021	Cognitive clusters in first-episode psychosis.
10/2021	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel J Cuesta Research Topics

Disease

53	Psychotic Disorders (Schizoaffective Disorder) 11/2022 - 12/2002
27	Schizophrenia (Dementia Praecox) 07/2022 - 01/2004
9	Parkinsonian Disorders (Parkinsonism) 06/2022 - 10/2006
7	Catatonia 06/2022 - 10/2006
7	Dyskinesias (Dyskinesia) 06/2022 - 10/2006
5	Mental Disorders (Mental Disorder) 01/2021 - 01/2004
5	Cognitive Dysfunction 10/2018 - 09/2014
4	Bipolar Disorder (Manic Depressive Psychosis) 06/2022 - 04/2011
4	Psychomotor Agitation (Akathisia) 10/2018 - 10/2006
3	Genetic Risk Score 06/2022 - 01/2020
3	Weight Gain 01/2021 - 01/2020
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 01/2021
2	Psychotic Affective Disorders 01/2021 - 03/2016
2	Movement Disorders (Movement Disorder) 01/2020 - 01/2014
2	Hypokinesia (Bradykinesia) 03/2012 - 06/2010
1	Cerebral Cortical Thinning 11/2022
1	Hallucinations (Hallucination) 10/2021
1	Substance-Related Disorders (Drug Abuse) 10/2021
1	Hyperglycemia 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2020
1	Obesity 01/2020
1	Birth Weight (Birth Weights) 01/2020
1	Atrophy 01/2020
1	Abdominal Obesity 01/2020
1	Aphasia (Dysphasia) 10/2018
1	Anhedonia 10/2018
1	Drug-Related Side Effects and Adverse Reactions 04/2016
1	Tremor (Tremors) 03/2012
1	Parkinson Disease (Parkinson's Disease) 03/2012
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/2011
1	Dystonia (Limb Dystonia) 01/2010

Drug/Important Bio-Agent (IBA)

35	Polytetrafluoroethylene (Teflon)FDA Link 11/2022 - 08/2012
22	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 05/2005
12	Pharmaceutical PreparationsIBA 01/2022 - 01/2010
5	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2022 - 03/2006
3	Biological ProductsIBA 01/2022 - 12/2002
3	Risperidone (Risperdal Consta)FDA LinkGeneric 05/2010 - 05/2009
3	Olanzapine (Zyprexa)FDA Link 05/2010 - 05/2009
2	Nerve Growth Factors (Neurotrophins)IBA 07/2022 - 01/2022
2	SDMIBA 04/2022 - 07/2021
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2020
2	EndocannabinoidsIBA 01/2019 - 01/2016
2	Cholinergic Antagonists (Anticholinergics)IBA 10/2018 - 04/2016
2	Silver Sulfadiazine (SSD)FDA LinkGeneric 03/2016 - 01/2016
2	Haloperidol (Haldol)FDA LinkGeneric 05/2010 - 01/2010
2	SolutionsIBA 04/2007 - 11/2005
1	Nerve Growth Factor (NGF)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	CholesterolIBA 01/2021
1	LDL CholesterolIBA 01/2021
1	IronIBA 01/2021
1	HDL CholesterolIBA 01/2020
1	Chlorpromazine (Thorazine)FDA Link 10/2018
1	Serotonin (5 Hydroxytryptamine)IBA 11/2017
1	amsonic acid (DAS)IBA 12/2016
1	Antidepressive Agents (Antidepressants)IBA 04/2016
1	BenzodiazepinesIBA 04/2016
1	Clozapine (Clozaril)FDA LinkGeneric 04/2016
1	TransferasesIBA 04/2012
1	catechol (pyrocatechol)IBA 04/2012
1	DysbindinIBA 04/2011
1	aminotris(methylenephosphonato)diamminoplatinum (II) (AMDP)IBA 05/2006
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 06/2004
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2004
1	CytokinesIBA 01/2004
1	N 30IBA 04/2003

Therapy/Procedure

4	Aftercare (After-Treatment) 10/2018 - 06/2010
1	Secondary Prevention 01/2022
1	Drug Therapy (Chemotherapy) 01/2020
1	Injections 04/2016